Search

everythinglearnresearchcommunity

for

Search:↓

A 29-year-old male shares progress pictures after 4 months using finasteride and 2% ketoconazole shampoo, noting initial shedding but overall improvement. He avoids minoxidil and microneedling, and reports thicker hair in balding areas while maintaining high water intake.

A trans man is experiencing hair loss due to testosterone therapy but is unwilling to stop the treatment despite concerns about using finasteride. The individual is distressed about balding at a young age but acknowledges it is genetic.

A user shared their positive experience with a hair transplant of 3500 grafts, showing significant improvement in appearance after 5 months. They underwent the procedure at Heva Clinic in Istanbul for $2,300 USD, which included aftercare, and attributed their hair loss to both genetics and traction alopecia from tight hairstyles.

Bicalutamide and spironolactone are being compared for their effectiveness and safety in treating female pattern hair loss. The conversation seeks advice on which is better to use.

The conversation is about using a product containing dutasteride and tamsulosin for hair loss. Users discuss separating the components and potential side effects like frequent urination and changes in libido.

The user has severe diffuse thinning on the scalp and is using finasteride, topical minoxidil, dermarolling, tretinoin, and Nizoral without satisfactory results. They are considering a hair transplant but are concerned about the cost and the number of grafts needed.

The conversation discusses disappointment over only receiving a financial report from Cassiopea instead of trial results for Breezula/CB-03-01, a hair loss treatment. However, there is optimism as the company is advancing Breezula into Phase III trials for men, starting trials for women, and submitting an NDA for their acne product, Winlevi.

Mixing Dutasteride with MCT oil may improve absorption due to its fat-soluble nature. Users suggest taking it with whole milk or using oil-based capsules for better effectiveness.

The conversation is about a hair loss treatment regimen that does not include finasteride. Specific treatments used are not mentioned.

A 40-year-old male using 1mg finasteride and Costco liquid minoxidil for almost 2 months reports noticeable improvement in hair regrowth, though his temples remain recessed. Encouragement from others suggests continued use will yield further progress.

Hair loss discussion includes fluridil (eucapil) and alfatradiol. Users share improvement experiences and alternative treatments in comments.

User started oral finasteride 0.33mg daily and later made a topical solution with cetirizine and stemoxydine. They experienced hair growth progress after 8-9 months and discussed factors affecting their results.

User creates 0.1% topical finasteride solution using Alfatradiol Avixis base. Seeks help to ensure alfatradiol base dissolves finasteride.

The user is using minoxidil, finasteride, dutasteride, and clobetasol, along with needling, to combat hair loss. They are considering stopping treatment if no improvement is seen.

A 31-year-old man shared his 2-year experience using finasteride and minoxidil after a hair transplant on the front and mid scalp, noting improvement but still having a thin crown. He recently started dermastamping, plans to use ketoconazole shampoo, and uses hair fibers for extra confidence at events.

The user experienced initial success with topical finasteride 0.025% and melatonin but noticed rapid hair thinning after three months. They are considering switching to a higher dose of topical finasteride or oral finasteride, as advised by others, while being cautious about potential side effects.

Clascoterone 5% topical solution shows promise for treating male-pattern hair loss by blocking DHT at the follicle without systemic absorption, potentially offering fewer side effects than oral treatments like finasteride. While results are promising, long-term safety and effectiveness need further study, and it may serve as a starting point for developing more effective treatments.

A user is using a Finoxidil topical spray and is curious if oral Finasteride would be more effective, considering they are already on a DHT blocker called Cyproterone. They are concerned about the potential impact of oral Finasteride on their transition.

A 30-year-old man shares his positive experience with hair loss treatment using finasteride, minoxidil, tretinoin, and ketoconazole shampoo over four months, noting significant hair regrowth and increased confidence. He plans to continue the regimen with occasional breaks and emphasizes the importance of critically evaluating information about treatment side effects.

The conversation is about obtaining pyrilutamide for hair loss treatment from China through a contact, with details on pricing and shipping. The user offers to facilitate the purchase and shipment for a small commission.

The conversation discusses the impact of finasteride on sperm, including potential side effects like decreased ejaculate volume and total sperm count. Users share experiences and concerns about fertility tests before and after starting finasteride.

A 34-year-old from Patna shared a 5-month update on his hair transplant, which involved 4,200 grafts using the FUE technique to cover the front and mid-scalp. He experienced initial shock loss but now sees natural-looking growth and improved density.

Kintor's 1% Pyrilutamide will be released in October/November. The user cannot tolerate finasteride.

Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.

A user shared their experience with a hair and beard transplant in Istanbul, performed by Dr. Selahattin Tulunay, noting successful results after 12 months. The procedure cost 5000 €, and the user is open to questions about combining procedures or traveling for surgery.

SCUBE3 is a promising new molecule that can restart hair growth by reawakening dormant hair follicles. Users express skepticism about its availability timeline, with some hoping for release by 2026.

GT20029 is discussed as a potential treatment for androgenetic hair loss by targeting androgen receptors, unlike finasteride which reduces DHT broadly. Concerns include its effectiveness, genetic variations in androgen receptors, and availability, with some skepticism about its potential as a true alternative.

A user traveled to Turkey for a 5000-graft FUE hair transplant at ASMED Clinic with Dr. Koray Erdogan. They used finasteride before and after the surgery and shared detailed experiences, costs, and recovery tips.

The conversation is about the anticipation of results for a hair loss treatment study, specifically for GT20029, with expectations for the results to be released in the first quarter of 2024. No specific treatments were discussed.

A new brand is seeking 10 U.S.-based individuals aged 25+ experiencing hair loss to test a topical product containing GHK-Cu and Acetyl Tetrapeptide-3. Participants must not be using other treatments like finasteride or minoxidil and will provide feedback and photos.